1-5 of 5
bromocriptine
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Erratum. Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes

J. Michael Gaziano, Anthony H. Cincotta, Christopher M. O’Connor, Michael Ezrokhi, Dean Rutty, Z.J. Ma, Richard E. Scranton
Journal: Diabetes Care
Diabetes Care 2016;39(10):1846
https://doi.org/10.2337/dc16-er10
Published: 13 September 2016
View article titled, Erratum. Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes
Open the PDF for Erratum. Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes in another window
Meeting Abstracts

Bromocriptine: a novel approach to the treatment of type 2 diabetes.

H Pijl, S Ohashi, M Matsuda, Y Miyazaki, A Mahankali, V Kumar, R Pipek, P Iozzo, J L Lancaster, A H Cincotta, R A DeFronzo
Journal: Diabetes Care
Diabetes Care 2000;23(8):1154–1161
https://doi.org/10.2337/diacare.23.8.1154
Published: 01 August 2000
View article titled, Bromocriptine: a novel approach to the treatment of type 2 diabetes.
Open the PDF for Bromocriptine: a novel approach to the treatment of type 2 diabetes. in another window
Meeting Abstracts

Lack of evidence for bromocriptine effect on glucose tolerance, insulin resistance, and body fat stores in obese type 2 diabetic patients.

T Wasada, R Kawahara, Y Iwamoto
Journal: Diabetes Care
Diabetes Care 2000;23(7):1039–1040
https://doi.org/10.2337/diacare.23.7.1039
Published: 01 July 2000
View article titled, Lack of evidence for bromocriptine effect on glucose tolerance, insulin resistance, and body fat stores in obese type 2 diabetic patients.
Open the PDF for Lack of evidence for bromocriptine effect on glucose tolerance, insulin resistance, and body fat stores in obese type 2 diabetic patients. in another window
Journal Articles

Effects of a Quick-Release Form of Bromocriptine (Ergoset) on Fasting and Postprandial Plasma Glucose, Insulin, Lipid, and Lipoprotein Concentrations in Obese Nondiabetic Hyperinsulinemic Women

Vinaya Kamath, MD, Claire N Jones, MD, Jeannie C Yip, MD, Ben B Varasteh, BS, Anthony H Cincotta, PHD, Gerald M Reaven, MD, Yii-Der I Chen, PHD
Journal: Diabetes Care
Diabetes Care 1997;20(11):1697–1701
https://doi.org/10.2337/diacare.20.11.1697
Published: 01 November 1997
View article titled, Effects of a Quick-Release Form of Bromocriptine (Ergoset) on Fasting and Postprandial Plasma Glucose, Insulin, Lipid, and Lipoprotein Concentrations in Obese Nondiabetic Hyperinsulinemic Women
Open the PDF for Effects of a Quick-Release Form of Bromocriptine (Ergoset) on Fasting and Postprandial Plasma Glucose, Insulin, Lipid, and Lipoprotein Concentrations in Obese Nondiabetic Hyperinsulinemic Women in another window
Journal Articles

Bromocriptine (Ergoset) Reduces Body Weight and Improves Glucose Tolerance in Obese Subjects

Anthony H Cincotta, Albert H Meier
Journal: Diabetes Care
Diabetes Care 1996;19(6):667–670
https://doi.org/10.2337/diacare.19.6.667
Published: 01 June 1996
View article titled, Bromocriptine (Ergoset) Reduces Body Weight and Improves Glucose Tolerance in Obese Subjects
Open the PDF for Bromocriptine (Ergoset) Reduces Body Weight and Improves Glucose Tolerance in Obese Subjects in another window